Nausea and Vomiting

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Nausea and vomiting during pregnancy (NVP) continue to challenge women and their providers. This chapter discusses the pathophysiology, diagnosis, treatment, complications, and preventions of NVP. Risk factors for NVP include an increased placental mass as seen with molar gestation or multiple gestations, a family history or personal history of hyperemesis gravidarum (HG), and a history of motion sickness or migraines. NVP exists as a spectrum of symptoms ranging in severity from mild and self-limited to severe and debilitating. Treatment of NVP varies with the severity of the disease and begins with non-pharmacological choices including dietary/lifestyle modification and vitamin/herbal supplementation, followed by pharmacological antiemetic therapy. When non-pharmacological approaches fail, breakthrough therapy using pharmacological agents is needed. The most common categories for use are antihistamines, dopamine antagonists, phenothiazines, and serotonin antagonists. Studies suggest that multivitamin use at the time of conception may be associated with a reduction of pregnancy-related nausea and vomiting.

Original languageEnglish (US)
Title of host publicationProtocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition
PublisherWiley Blackwell
Pages298-305
Number of pages8
ISBN (Electronic)9781119001256
ISBN (Print)9781119000877
DOIs
StatePublished - Jan 1 2015

Fingerprint

Nausea
Vomiting
Pregnancy
Hyperemesis Gravidarum
Pharmacology
Motion Sickness
Phenothiazines
Diet Therapy
Serotonin Antagonists
Antiemetics
Dopamine Antagonists
Histamine Antagonists
Therapeutics
Migraine Disorders
Vitamins
Life Style

Keywords

  • Breakthrough therapy
  • Hyperemesis gravidarum (HG)
  • Molar gestation
  • Nausea and vomiting during pregnancy (NVP)
  • Pharmacological antiemetic therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Olson, G. (2015). Nausea and Vomiting. In Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition (pp. 298-305). Wiley Blackwell. https://doi.org/10.1002/9781119001256.ch36

Nausea and Vomiting. / Olson, Gayle.

Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition. Wiley Blackwell, 2015. p. 298-305.

Research output: Chapter in Book/Report/Conference proceedingChapter

Olson, G 2015, Nausea and Vomiting. in Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition. Wiley Blackwell, pp. 298-305. https://doi.org/10.1002/9781119001256.ch36
Olson G. Nausea and Vomiting. In Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition. Wiley Blackwell. 2015. p. 298-305 https://doi.org/10.1002/9781119001256.ch36
Olson, Gayle. / Nausea and Vomiting. Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition. Wiley Blackwell, 2015. pp. 298-305
@inbook{c8ec8b4962bc4c29a4b28cf6abfa26e6,
title = "Nausea and Vomiting",
abstract = "Nausea and vomiting during pregnancy (NVP) continue to challenge women and their providers. This chapter discusses the pathophysiology, diagnosis, treatment, complications, and preventions of NVP. Risk factors for NVP include an increased placental mass as seen with molar gestation or multiple gestations, a family history or personal history of hyperemesis gravidarum (HG), and a history of motion sickness or migraines. NVP exists as a spectrum of symptoms ranging in severity from mild and self-limited to severe and debilitating. Treatment of NVP varies with the severity of the disease and begins with non-pharmacological choices including dietary/lifestyle modification and vitamin/herbal supplementation, followed by pharmacological antiemetic therapy. When non-pharmacological approaches fail, breakthrough therapy using pharmacological agents is needed. The most common categories for use are antihistamines, dopamine antagonists, phenothiazines, and serotonin antagonists. Studies suggest that multivitamin use at the time of conception may be associated with a reduction of pregnancy-related nausea and vomiting.",
keywords = "Breakthrough therapy, Hyperemesis gravidarum (HG), Molar gestation, Nausea and vomiting during pregnancy (NVP), Pharmacological antiemetic therapy",
author = "Gayle Olson",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/9781119001256.ch36",
language = "English (US)",
isbn = "9781119000877",
pages = "298--305",
booktitle = "Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Nausea and Vomiting

AU - Olson, Gayle

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Nausea and vomiting during pregnancy (NVP) continue to challenge women and their providers. This chapter discusses the pathophysiology, diagnosis, treatment, complications, and preventions of NVP. Risk factors for NVP include an increased placental mass as seen with molar gestation or multiple gestations, a family history or personal history of hyperemesis gravidarum (HG), and a history of motion sickness or migraines. NVP exists as a spectrum of symptoms ranging in severity from mild and self-limited to severe and debilitating. Treatment of NVP varies with the severity of the disease and begins with non-pharmacological choices including dietary/lifestyle modification and vitamin/herbal supplementation, followed by pharmacological antiemetic therapy. When non-pharmacological approaches fail, breakthrough therapy using pharmacological agents is needed. The most common categories for use are antihistamines, dopamine antagonists, phenothiazines, and serotonin antagonists. Studies suggest that multivitamin use at the time of conception may be associated with a reduction of pregnancy-related nausea and vomiting.

AB - Nausea and vomiting during pregnancy (NVP) continue to challenge women and their providers. This chapter discusses the pathophysiology, diagnosis, treatment, complications, and preventions of NVP. Risk factors for NVP include an increased placental mass as seen with molar gestation or multiple gestations, a family history or personal history of hyperemesis gravidarum (HG), and a history of motion sickness or migraines. NVP exists as a spectrum of symptoms ranging in severity from mild and self-limited to severe and debilitating. Treatment of NVP varies with the severity of the disease and begins with non-pharmacological choices including dietary/lifestyle modification and vitamin/herbal supplementation, followed by pharmacological antiemetic therapy. When non-pharmacological approaches fail, breakthrough therapy using pharmacological agents is needed. The most common categories for use are antihistamines, dopamine antagonists, phenothiazines, and serotonin antagonists. Studies suggest that multivitamin use at the time of conception may be associated with a reduction of pregnancy-related nausea and vomiting.

KW - Breakthrough therapy

KW - Hyperemesis gravidarum (HG)

KW - Molar gestation

KW - Nausea and vomiting during pregnancy (NVP)

KW - Pharmacological antiemetic therapy

UR - http://www.scopus.com/inward/record.url?scp=85018372712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018372712&partnerID=8YFLogxK

U2 - 10.1002/9781119001256.ch36

DO - 10.1002/9781119001256.ch36

M3 - Chapter

SN - 9781119000877

SP - 298

EP - 305

BT - Protocols for High-Risk Pregnancies: An Evidence-Based Approach: Sixth Edition

PB - Wiley Blackwell

ER -